annonceHomeUS

TG4050First positive data from Phase I clinical trials Press release [PDF] Initial data presented at the ASCO congress (June 2022) Interview of the team and Pr Ottensmeier on the data (November 2022)

esmo

ESMO 2021 Transgene presents data confirming the potential of oncolytic virus TG6002 administered intravenously Donwload Press release (PDF) TG6002 en images

annonce substitut

A particularly innovative immunotherapy, TG4050 is the lead myvac® candidate. This individualized treatment is based on the specific mutations that are identified in each patient’s tumor. TG4050 video

annonce

One cancer, one patient, one vaccine With TG4050, Transgene is developing an individualized immunotherapy based on advanced genetic engineering and artificial intelligence (AI) technologies. The treatment is based on an optimized MVA viral vector. myvac® video Each treatment is designed and manufactured by Transgene for each patient, targeting the most relevant tumor targets (cancer-specific neoantigens)… Continue reading annonce

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00

 

© 2021 Transgene - All rights reserved
Terms of use - Credits